The selection process itself signals how far Kirabo’s ideas have traveled. Recipients are chosen by the editors-in-chief of the American Heart Association’s 14 peer-reviewed scientific journals, and the award explicitly celebrates research that transforms or changes the direction of cardiovascular science. In Kirabo’s case, the transformation is easy to trace. For decades, hypertension was understood primarily as a disorder of blood vessels, kidneys, and the nervous system — a plumbing problem of constricted arteries and sodium retention. Her research demonstrated that the immune system is not a bystander in this process but an active participant, with immune cell activation and inflammatory signaling capable of driving vascular dysfunction and elevating blood pressure. That reframing has reshaped how investigators around the world approach the mechanisms of hypertension and, increasingly, how they search for new drugs against it.

The technical core of Kirabo’s most influential work lies in the chemistry of lipid oxidation. When fats in the body undergo oxidation, they generate highly reactive molecules that can chemically modify proteins, forming what are known as lipid oxidation-derived protein adducts. Kirabo’s laboratory showed that these altered proteins act as neoantigens — molecular patterns that the immune system can recognize as foreign even though they arise from the body’s own tissues. When antigen-presenting cells encounter these neoantigens, they become activated and in turn stimulate T-cell responses. Those T cells, a central arm of adaptive immunity, then contribute to vascular dysfunction, promoting the endothelial impairment and inflammatory milieu that ultimately raise blood pressure. The discovery provided a mechanistic bridge between oxidative stress, a long-recognized feature of hypertension, and the immune activation that accompanies it, fundamentally changing scientific understanding of how the immune system contributes to blood pressure regulation.

That bridge has proven to be a productive place to build. Kirabo’s subsequent work has identified potential therapeutic targets arising directly from this immune-centered model of hypertension, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways operating in immune cells. Isolevuglandins are among the most reactive products of lipid peroxidation, capable of cross-linking and irreversibly modifying proteins, and their accumulation has been implicated in the formation of the very protein adducts that trigger immune recognition. Sodium-sensing pathways in immune cells, meanwhile, suggest a mechanism by which dietary salt — the classic environmental driver of hypertension — might act directly on immune cells to promote their activation, linking a nutritional exposure to an immunological response. Together, these lines of investigation have opened possibilities for preventing and treating hypertension and related cardiovascular and kidney diseases that extend well beyond conventional approaches centered on diuretics, vasodilators, and blockers of the renin-angiotensin system.

Manesh R. Patel, M.D., FAHA, the American Heart Association’s 2026-2027 volunteer president and the Richard S. Stack, M.D. Distinguished Professor of Medicine at Duke University, framed the significance of the work in announcing the award. “Dr. Annet Kirabo exemplifies the spirit of the Joseph A. Vita Award, which recognizes research that changes the direction of cardiovascular science,” Patel said. “Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease. Through innovative, multidisciplinary research, she has uncovered potential therapeutic targets, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways in immune cells, that have opened exciting possibilities for preventing and treating hypertension and related cardiovascular and kidney diseases.”

The scope of Kirabo’s research program reflects the multidisciplinary approach that Patel described. Her laboratory today combines immunology, vascular biology, genomics, metabolomics, and single-cell technologies to identify new therapeutic strategies for cardiovascular and kidney disease. Single-cell approaches, in particular, have become a powerful tool in immunology, allowing researchers to resolve the heterogeneity of immune cell populations that bulk measurements average away — a capability well suited to dissecting which subsets of T cells and antigen-presenting cells participate in hypertensive vascular injury. Metabolomics and lipidomics, for their part, allow the reactive lipid species at the heart of her model to be catalogued and quantified, connecting the chemistry of oxidation to the cellular biology of inflammation. Her research spans the full spectrum of discovery science, from defining fundamental disease mechanisms to advancing translational research with the potential to transform patient care.

The scientific output behind the award is substantial. Kirabo has authored more than 230 scientific publications, sustained funding from the National Institutes of Health, and published numerous influential articles in the American Heart Association’s journals — a criterion directly relevant to an award named for the founding editor of one of them. Her work has established new directions in cardiovascular science and continues to influence investigators worldwide, particularly those studying the intersection of inflammation, oxidative stress, and vascular disease. The immune hypothesis of hypertension that her findings helped establish is now a recognized framework within the field, informing studies of hypertensive end-organ damage in the kidney, heart, and brain as well as the vasculature itself.

Kirabo’s relationship with the American Heart Association extends well beyond this year’s award. She has been an active volunteer with the organization since 2009, serving on the Council on Hypertension Communications Committee since 2018, including as its chair from 2022 to 2024, and on the Council Operations Committee since 2024. She has reviewed Association research proposals since 2017 and chaired sessions at scientific meetings in 2018, 2022, and 2023. Her editorial service includes membership on the editorial board of the journal Hypertension since 2018 and an associate editorship at Circulation Research since 2019 — roles that place her at the gatekeeping junction of the same journals whose editors selected her for the Vita Award.

Her scientific trajectory is itself a story of international training and reinvention. Kirabo earned her doctor of veterinary medicine degree with honors from Makerere University in Uganda before completing a master of science in cell and molecular biology at St. Cloud State University in Minnesota and a doctorate in physiology and functional genomics at the University of Florida in Gainesville. She then completed postdoctoral training in cardiovascular disease and inflammation at Vanderbilt University, where she now leads an internationally recognized research program. In her own words, the recognition carries personal weight. “I am deeply honored to receive the Joseph A. Vita Award from the American Heart Association, an organization that has supported my career from my predoctoral and postdoctoral fellowships through my development as an independent investigator,” Kirabo said. “Scientific discovery, mentorship and advancing new treatments for cardiovascular disease have been the primary focus of my career, and it is both rewarding and humbling to be recognized for it.”

Beyond her laboratory’s discoveries, Kirabo’s influence on the field runs through the scientists she has trained. A dedicated mentor and educator, she has trained dozens of graduate students, postdoctoral fellows, and early-career investigators, many of whom have gone on to faculty positions and independent research careers of their own. Her commitment to mentorship, scientific collaboration, and innovation continues to shape the future of cardiovascular research while expanding opportunities for emerging scientists around the world. As hypertension remains the leading modifiable risk factor for premature death globally, the recognition of work that reframed the disease as an immunological as well as a hemodynamic disorder underscores a broader lesson in biomedical science: the most transformative discoveries often come from looking at a familiar problem through an entirely different disciplinary lens.

Subject of Research: The role of immune activation and inflammation in hypertension, recognized by the 2026 Joseph A. Vita Award

Article Title: Scientist whose work revealed immune system-hypertension link to receive the 2026 Joseph A. Vita Award

Article References: Scientist whose work revealed immune system-hypertension link to receive the 2026 Joseph A. Vita Award. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hypertension, immunology, inflammation, isolevuglandins, T cells, neoantigens, lipid oxidation, vascular biology, American Heart Association, Joseph A. Vita Award, Vanderbilt University, cardiovascular disease

The Innovative Project Award provides $200,000 over two years and is deliberately designed to back high-risk, high-reward science. Eligible projects spanned the full breadth of biomedical inquiry, from basic laboratory studies of cells and molecules to clinical investigations and population health research, and applicants could propose work across the entire human lifespan, from children and adolescents through middle age and late life. The prioritization of innovation over incremental safety reflects a conscious strategy by both societies: rather than extending established research programs, they wanted to seed ideas that conventional funding mechanisms might consider too speculative, but that could open entirely new avenues for preventing stroke and heart disease in people living with chronic headache disorders.

This year’s co-funded award goes to Juliana Navia Pelaez, Ph.D., an assistant professor at St. Louis University School of Medicine in St. Louis, Missouri, for a project titled “Neurogenic Priming of Perivascular Macrophages by Migraine-Associated Peptides Increases Stroke Risk.” Her work targets a question that has long puzzled clinicians: why some people who suffer from migraine face a higher risk of stroke. Researchers have traditionally concentrated on the blood vessels themselves, since during a migraine attack these vessels may tighten, swell, or alter the way blood moves through them. But attention is now shifting toward another, less obvious player — the brain’s own resident immune cells, which stand guard along the vessels and help protect neural tissue from injury.

Pelaez’s central hypothesis is that repeated migraine attacks may push these vascular immune cells into a state of chronic overactivation. “If migraines happen over and over, these immune cells might stay ‘on’ for too long. When this happens, they might accidentally make the blood vessels weaker,” Pelaez said. “If the vessels get weaker, the brain might have a harder time protecting itself from a stroke.” In practical terms, the project will map which signals released during a migraine activate these brain immune cells, and then compare how the cells respond to a subsequent stroke in animals that have experienced migraine-like events versus those that have not. The comparison is designed to isolate the specific contribution of migraine biology to stroke vulnerability, rather than attributing everything to shared risk factors such as hypertension or smoking.

The translational implications could be considerable. “If our idea is right,” Pelaez added, “this could help scientists find new ways to prevent strokes in people with chronic migraine, maybe by calming these overactive brain cells or blocking the signals that bother them.” Such a strategy would represent a fundamentally different approach to stroke prevention in this population. Instead of managing vascular risk factors after the fact, clinicians might one day intervene directly on the neuroimmune signaling cascade that links repeated migraine attacks to cumulative vessel damage — a possibility that could reshape how neurologists and cardiologists jointly manage patients with frequent or chronic migraine.

The Heart Association’s three additional awards extend the same investigative ambition across distinct mechanistic frontiers. The first goes to Andrea M. Harriott, M.D., Ph.D., an assistant professor in neurology at Massachusetts General Hospital in Boston, for a study titled “The Impact Of Cortical Spreading Depolarizations On Endothelial Phenotype, Neovascularization, and Collateral Remodeling.” Migraine with aura has long been epidemiologically linked to stroke and heart attack, and earlier thinking held that this association might simply reflect an elevated burden of conventional risk factors among people with aura. Harriott’s project will test a more direct possibility: that the long-term exposure to the mechanisms underlying migraine aura — cortical spreading depolarizations, waves of altered electrical and metabolic activity that sweep across the brain — causes lasting structural and functional harm to cerebral blood vessels. Her team will examine protein-level changes in the cells lining vessel walls, the formation of new blood vessels, and the remodeling of collateral circulation that the brain relies on when its primary supply routes are compromised.

The second award supports Matthew T. Bender, M.D., an associate professor at the University of Rochester in Rochester, New York, whose project, “Defining The Glymphatic-Hemodynamic Axis In IIH: A Novel Multi-Scale Quantitative MRI Framework,” addresses idiopathic intracranial hypertension, or IIH. This headache disorder disproportionately affects overweight women of childbearing age, and clinicians believe it arises from elevated pressure inside the skull driven by excess cerebrospinal fluid. Recent evidence, however, suggests the disorder may also involve dysfunction of the brain’s waste clearance network, known as the glymphatic system. Bender’s team will develop a new magnetic resonance imaging framework capable of visualizing both the glymphatic system and cerebral blood flow without contrast dye or invasive procedures. By scanning IIH patients before and after venous stenting — a procedure that opens narrowed veins draining the brain — the researchers hope to determine how restoring venous outflow affects waste clearance and hemodynamics, potentially establishing imaging markers that could guide treatment decisions.

The third award funds Neil Dani, Ph.D., an assistant professor at Vanderbilt University in Nashville, Tennessee, for “Illuminating Nociceptive And Analgesic Mechanisms Of Choroid Plexus In Migraine And Obesity Models.” Dani’s work responds to the rising prevalence of obesity-related migraine, a clinically important overlap given that both conditions share inflammatory signaling pathways. His focus is the choroid plexus, a small structure inside the brain’s ventricles that produces cerebrospinal fluid and acts as a highly regulated interface, or gate, between the body and the central nervous system. The working hypothesis is that inflammatory signals generated in the body during obesity may travel through the cerebrospinal fluid via the choroid plexus, sensitizing pain circuits and increasing migraine frequency or severity. The project will characterize inflammation patterns in this structure, identify cellular rewiring and immune signaling changes associated with obesity and migraine, and test whether clinically approved drugs — including acetazolamide, a long-standing medication already used in related contexts — can reduce both swelling and pain signaling in experimental models.

Taken together, the four projects sketch a research landscape in which headache disorders and vascular medicine are no longer treated as separate silos. Each award interrogates a different node of the heart-brain axis: immune cells that patrol cerebral vessels, the electrical storms of migraine aura and their vascular aftermath, the interplay of intracranial pressure and brain waste clearance, and the inflammatory crosstalk between metabolism, body-wide immune signaling, and pain. The funders emphasize that these efforts demonstrate the shared commitment of the American Headache Society and the American Heart Association to advancing brain health research, and the co-funding structure itself may prove as influential as the science it supports, encouraging cross-disciplinary training, shared patient cohorts, and unified endpoints across neurology and cardiology.

The initiative also sits within a far larger funding tradition. Supporting scientific research and discovery through programs of this kind is a cornerstone of the century-old American Heart Association’s lifesaving mission. Since 1949, the Association has invested more than $6.3 billion in cardiovascular, cerebrovascular, and brain health research, making it the single largest non-profit, non-governmental supporter of heart and brain health research in the United States. Officials note that knowledge generated through this funding continues to save lives and directly affect millions of people across the country and around the world. For the millions who live with migraine and other headache disorders — and for the clinicians who care for them — the new awards offer something more immediate than long-term promise: a concrete, funded research agenda that treats the pounding in the head and the health of the heart and brain’s vessels as inseparable parts of the same biological story.

Subject of Research: Funded research projects investigating the links between migraine, headache disorders, and cardiovascular and cerebrovascular health

Article Title: New scientific research projects study heart/brain connection to migraines, headaches

Article References: New scientific research projects study heart/brain connection to migraines, headaches. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: migraine, stroke, American Heart Association, American Headache Society, cerebrovascular health, cortical spreading depolarization, idiopathic intracranial hypertension, glymphatic system, choroid plexus, perivascular macrophages, obesity-related migraine, research funding

The scale of the question is enormous. Between 50 and 72 percent of hospitalized patients carry a hypertension diagnosis, and roughly three-quarters experience at least one elevated blood pressure reading during their stay. Acute, symptomatic spikes that cause end-organ damage, known as hypertensive emergencies, demand rapid, high-intensity treatment. But for readings that fall well short of emergency territory and produce no symptoms, the evidence for intervening is remarkably thin, and what observational data exist point in a troubling direction: intensifying antihypertensive medications in the hospital may actually harm patients.

Those signals of harm are not subtle. In a propensity-matched cohort study, hospitalized patients who received antihypertensive medication on an as-needed basis had 24 percent higher odds of acute kidney injury, more than eight times the odds of ischemic stroke, and more than triple the odds of inpatient mortality. Intravenous antihypertensives, in particular, have been linked to prolonged hospital stays, while even oral intensification has been associated with kidney and myocardial injury. Worse, treating elevated blood pressure in the hospital does not appear to improve long-term blood pressure control and may raise the risk of adverse outcomes in the 30 days after discharge.

Recognizing this uncertainty, the American Heart Association issued a Scientific Statement in May 2024 concluding that the risk-benefit ratio of prescribing antihypertensives for asymptomatic elevated inpatient readings is unclear. Blood pressure can rise transiently because of pain, nausea, temperature, or stress, and in those cases the underlying cause, not the number on the monitor, is the appropriate target. But at some threshold, presumably, treatment becomes worthwhile. Where that threshold lies has never been established, which is precisely why a team led by Elizabeth R. Pfoh of the Cleveland Clinic set out to map what physicians actually think.

Between February and October 2024, the researchers emailed anonymous surveys to hospitalists at five academic medical centers: the Cleveland Clinic, Johns Hopkins School of Medicine, the University of Utah School of Medicine, the University of Nebraska Medical Center, and the University of Wisconsin-Madison. They defined elevated blood pressure as readings between 140/90 and 210/120 mmHg without symptoms of hypertensive emergency, deliberately excluding crises from the picture. Of 397 potential respondents, 166 physicians replied, an overall response rate of 42 percent that ranged from 24 to 64 percent across sites. Because the survey straddled the release of the AHA statement, the team also ran a sensitivity analysis comparing sites surveyed before and after May 2024.

The headline finding was a near-even split of professional opinion. When asked whether it is important to treat patients with an elevated blood pressure, 27 percent of hospitalists agreed while 47 percent disagreed, and the remaining quarter were neutral. On average, respondents leaned neutral overall, with a mean score of 3.3 on a five-point scale, but that average concealed a polarized profession: 8 percent strongly agreed treatment was warranted, 19 percent agreed, 30 percent disagreed, and 17 percent strongly disagreed. These attitudes were remarkably consistent across all five institutions, suggesting the divide is not a local quirk but a national pattern.

When it came to numbers, physicians converged loosely around a threshold but disagreed on the details. The median systolic trigger for intensifying medication was 170 to 179 mmHg, yet 38 percent of physicians said they would intensify below 169 mmHg, while 24 percent would hold off until readings reached at least 180 to 189 mmHg. Patience, however, was nearly universal: 79 percent of physicians would wait at least 12 hours before acting on an elevated reading. Patient characteristics mattered even more than the raw numbers. Physicians reported being more likely to treat patients with a history of heart failure (73 percent), stroke (73 percent), myocardial infarction (64 percent), or coronary disease (57 percent), and markedly less likely to treat patients whose elevated readings plausibly stemmed from withdrawal symptoms (81 percent less likely), pain (79 percent), fall risk (77 percent), substance use (61 percent), or nausea (53 percent).

Perhaps the most provocative finding concerned who, in practice, drives treatment. Sixty percent of physicians agreed that treatment is driven by nurses calling physicians, and an overwhelming 89 percent agreed they would prefer not to be contacted by a nurse about an asymptomatic systolic reading below 170 mmHg. Physicians who were least inclined to treat agreed most strongly that nursing calls were pushing them to prescribe, and they expressed the strongest preference for silence below both 170 and even 200 mmHg. The free-text responses laid bare the mechanism: repeated nursing calls create pressure to do something, and for many physicians, the perceived risk of prescribing feels smaller than the discomfort of ignoring an alarm. The AHA’s own framework, which urges hospitals to modify the culture of unnecessary treatment cascades, including default nurse-notification orders, appears aimed squarely at this dynamic.

Qualitative analysis of 133 open-ended responses revealed three broad rationales. Some physicians rejected routine treatment outright, with comments such as increasing medications without symptoms or clear indications puts the patient at higher risk for damage than benefit. Others would treat only when readings remained persistently elevated, for example beyond 24 hours, without another explanation. A third group would act only at very high values, though what counted as very high ranged from above 170 to over 200 mmHg. Underlying it all were two cross-cutting concerns: patient-specific conditions such as heart failure, and process worries such as poor outpatient follow-up after discharge. Meanwhile, only about a quarter of physicians felt there was clear guidance on when to prescribe, and 79 percent strongly disagreed that intravenous medication should ever be used for asymptomatic elevations, a view that hardened further among sites surveyed after the AHA statement.

The survey’s limitations are worth noting. It captured only academic medical centers in five states, response rates were moderate, and anonymity precluded comparisons between responders and non-responders, raising the possibility that physicians with strong opinions were more likely to reply. It is also possible that respondents imagined intensification as a permanent regimen change rather than a single dose, which could have shaped their answers. Still, the picture that emerges is of a profession practicing without a map. A 2024 systematic review found no guidelines at all for asymptomatic elevated inpatient blood pressure, only ten for hypertensive urgencies and eleven for emergencies. Compared with a 2010 survey in which 80 percent of residents called inpatient blood pressure control a high priority, the finding that just 27 percent of today’s hospitalists agree treatment is important suggests opinion has shifted as evidence of harm has accumulated. The authors conclude that randomized trial evidence is urgently needed to inform evidence-based guidelines, which in turn could reduce the wide practice variation that currently governs one of the most common decisions in hospital medicine. Until then, the most defensible approach, the researchers suggest, is the one the evidence already supports: treat the pain, the nausea, the stress, and the underlying illness, and let a truly asymptomatic number wait.

Subject of Research: Hospitalist attitudes toward treating asymptomatic elevated blood pressure readings in hospitalized patients

Article Title: Physicians’ Beliefs About Treating Asymptomatic Elevated Blood Pressure Readings Among Hospitalized Patients

Article References: Pfoh, E. R., Harris, C. M., Singh, M., Pappas, M. A., Ellenbogen, M. I., Shiffermiller, J., Kaiksow, F. A. A., Vaughn, V. M., & Rothberg, M. B. (2026). Physicians’ Beliefs About Treating Asymptomatic Elevated Blood Pressure Readings Among Hospitalized Patients. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10708-9

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10708-9

Keywords: hypertension, hospitalized patients, hospital medicine, antihypertensive medication, blood pressure, American Heart Association, inpatient care, physician survey, overtreatment, clinical guidelines, nursing calls, patient safety

Houston-based PolyVascular took the top honor in the AHA’s annual Health Tech Competition, securing the overall best in business category for its groundbreaking approach to congenital heart disease. Their minimally invasive valve technology is engineered to reduce the trauma and risks associated with repeated open-heart surgeries in pediatric patients. This technology is uniquely designed with an expandable valve that grows alongside the child, fundamentally altering the management of this complex condition by reducing cumulative surgical interventions. The significance of this technology is underscored by its alignment with AHA’s mission to bring scalable health solutions directly to patients, addressing the unmet needs within vulnerable pediatric populations.

The scientific category winner, Brainomix emerges from Oxford, England, advancing artificial intelligence-powered software that supports precision medicine for neurological conditions such as stroke and lung fibrosis. Brainomix’s AI algorithms enhance diagnostic accuracy and optimize treatment decision-making in real-time clinical settings, thereby reducing treatment delays and improving patient prognoses. This technology leverages large datasets and continuous learning models to refine medical decision support systems, fostering personalized and evidence-driven interventions that could revolutionize acute stroke care.

The Health Tech Competition serves as an incubator and showcase for innovations specifically targeting the prevention and treatment of cardiovascular and cerebrovascular diseases. Finalists presented diverse solutions spanning a spectrum of clinical issues: from PolyVascular’s pediatric heart disease innovations to AI-driven platforms supporting hypertension and metabolic disorder management. The event highlighted the potential for digital health technologies to bridge gaps in care delivery by embedding themselves within patients’ daily environments, whether at home, work, or in recreational settings.

Selection criteria for the competition hinged on three foundational pillars: validity, scientific rigor, and impact. Validity assessed the market readiness and functional deployment of the product prototypes among real-world users. Scientific rigor evaluated the extent to which each innovation was underpinned by robust, evidence-based health research methodologies. Impact measured the degree to which the technology could tangibly improve patient outcomes through novel, effective mechanisms. This comprehensive evaluative approach ensured that innovations were not only creative but also pragmatic and scalable.

Among the distinguished finalists were Boston’s Lumia, introducing wearable devices designed to assist individuals with orthostatic intolerance and chronic blood flow disorders. These wearables integrate physiological monitoring technologies that detect aberrations in autonomic nervous system function, potentially enabling early interventions before exacerbation of symptoms. Berlin’s Noah Labs utilized voice data transformation into digital biomarkers, providing a novel, non-invasive avenue for early detection and management of cardiometabolic diseases, encapsulating the power of digital phenotyping in modern medicine.

San Francisco-based Cambrian Health introduced an AI-enabled platform engineered to embed clinical best practices seamlessly into point-of-care environments. By automating guideline adherence and clinical decision pathways, Cambrian aims to eliminate variability in care delivery, enhancing outcomes through consistency and precision. This intersection of artificial intelligence and clinical protocols reflects a growing trend in healthcare innovation focused on augmenting clinician capabilities with smart technology.

PolyVascular’s technological breakthrough embodies a paradigm shift in the treatment of congenital heart defects, where traditional surgical approaches impose repeated bodily trauma and long-term recovery burdens on young patients. The device’s minimally invasive deployment mechanism, coupled with its capacity for expansion, mitigates growth-related challenges, effectively “growing” with the child to reduce the frequency of invasive procedures. This innovation not only enhances clinical outcomes but also significantly improves quality of life by minimizing hospital stays and associated psychological stress for families.

Brainomix’s AI-based solutions introduce an era of enhanced stroke care marked by rapid, accurate diagnostic processes and individualized treatment algorithms. By integrating advanced machine learning models into clinical workflows, Brainomix augments clinician judgment with predictive analytics and pattern recognition, accelerating timely interventions essential for minimizing ischemic damage. This approach signifies a pivotal advancement in bringing precision medicine from concept to practice, particularly in high-stakes, time-sensitive neurological emergencies.

The prestigious panel of judges for the Health Tech Competition comprised leading experts spanning cardiology, health innovation, venture capital, and medical technology sectors. Their diverse perspectives ensured a rigorous evaluative process balancing scientific merit, entrepreneurial viability, and clinical impact. Notable figures included Dr. Eric D. Peterson of UT Southwestern, Dr. Lee Shapiro of 7WireVentures, and Dr. Joseph C. Wu of the Stanford Cardiovascular Institute, among others, highlighting a collaborative nexus of academic scholarship and industry leadership.

The live presentations, conducted over two days at the Ernest N. Morial Convention Center during the AHA’s Scientific Sessions 2025, provided a dynamic platform for finalists to demonstrate real-world applications and future potential of their technologies. This forum fostered cross-disciplinary dialogue and collaboration opportunities, potentially accelerating pathways from innovation to clinical implementation. The competition exemplifies the AHA’s commitment to not only funding research but actively cultivating the translation of innovations into accessible, impactful healthcare solutions.

As cardiovascular and neurological diseases continue to impose profound individual and societal burdens, the integration of advanced technologies such as minimally invasive devices and AI-driven diagnostic tools offers a beacon of hope. The achievements of PolyVascular and Brainomix underscore the transformative potential held at the intersection of engineering, medicine, and artificial intelligence. Continued efforts in this domain parallel calls for equitable healthcare innovation that reaches patients holistically, encompassing prevention, timely diagnosis, and effective management.

The American Heart Association’s Center for Health Technology & Innovation Innovators’ Network further solidifies the critical infrastructure supporting the evolution of healthcare technologies. By connecting a consortium of entrepreneurs, clinicians, researchers, and payers, this collaborative ecosystem accelerates the dissemination and refinement of technologies destined to redefine standards of care. This inclusive approach ensures that solutions not only change clinical outcomes but also address health disparities and systemic barriers across diverse populations.

Ultimately, the outcomes of the 2025 Health Tech Competition highlight a future where cardiovascular and brain health management is increasingly personalized, less invasive, and powered by intelligent systems. The pioneering innovations showcased promise to reshape patient experiences, reduce healthcare costs, and elevate overall health outcomes—fulfilling the American Heart Association’s enduring mission to foster longer, healthier lives worldwide.

Subject of Research: Innovative health technologies targeting cardiovascular and cerebrovascular disease, with a focus on pediatric congenital heart disease and AI-enhanced stroke care.

Article Title: Pioneering Health Technologies Transform Cardiovascular and Brain Disease Care: Insights from the 2025 American Heart Association Health Tech Competition

News Publication Date: November 10, 2025

Web References:

• https://ahahealthtech.org/aha-health-tech-competition-2025/
• https://newsroom.heart.org/news/finalists-named-in-global-health-technology-competition-to-advance-heart-and-brain-health

Keywords: Cardiovascular disease, stroke, congenital heart disease, artificial intelligence, health tech, pediatric cardiology, precision medicine, digital health, wearable technology, minimally invasive surgery

Dr. Hochman’s career exemplifies a commitment to transforming cardiovascular care through rigorous scientific inquiry. As founding co-director of the NYU Langone Health Clinical and Translational Science Institute and Harold Snyder Family Professor of Cardiology, she has spearheaded pivotal international clinical trials that have reshaped global cardiology practice guidelines. Her involvement in National Heart, Lung, and Blood Institute (NHLBI)-funded studies underscores her role in bridging experimental research findings to tangible therapeutic strategies.

Among her landmark contributions is the Occluded Artery Trial (OAT), which challenged prevailing assumptions about late reperfusion in post-myocardial infarction patients. Building upon preclinical studies demonstrating favorable left ventricular remodeling in rodent models, OAT tested whether late angioplasty conveyed clinical benefits in stable post-infarct patients. Contrary to expectations set by animal data, the trial conclusively showed no significant improvement in outcomes, providing critical evidence against routine late invasive procedures and reshaping clinical decision-making on this front.

The SHOCK Trial represents another cornerstone of Dr. Hochman’s research portfolio. Focused on patients experiencing cardiogenic shock following acute myocardial infarction, this trial rigorously evaluated the survival advantage of emergent revascularization strategies versus conventional medical management. The results were definitive: early revascularization yielded a substantial 13-percentage-point reduction in mortality at one year and in long-term follow-up, transforming the treatment paradigm for this critically ill patient population and increasing adoption of aggressive intervention in clinical settings worldwide.

More recently, Dr. Hochman directed the ISCHEMIA trial, an ambitious NHLBI-sponsored international study designed to compare invasive versus conservative management strategies in stable coronary artery disease. This trial provided nuanced insights by revealing no significant difference in all-cause mortality between the two approaches. However, it highlighted meaningful enhancements in quality of life for patients suffering from angina who underwent invasive procedures such as coronary angiography, percutaneous coronary intervention, or coronary artery bypass grafting. These findings have informed guidelines by emphasizing patient-centered outcomes alongside survival metrics.

The synthesis of these trials has directly informed updates to pivotal clinical practice guidelines issued jointly by the American Heart Association and the American College of Cardiology, as well as recommendations from global cardiovascular societies. Dr. Hochman’s influence extends beyond research; she has actively contributed to multiple guideline writing committees, thereby embedding her evidence-based findings into the framework that shapes everyday cardiology practice internationally.

In addition to her impact on revascularization strategies, Dr. Hochman has been a pioneering voice in women’s cardiovascular health. Her early recognition of sex differences in acute coronary syndromes during the Thrombolysis In Myocardial Infarction IIIb (TIMI IIIb) trial paved the way for a deeper scientific understanding that many women with these syndromes exhibit no obstructive coronary artery disease. This revelation has sparked renewed attention on gender-specific pathophysiology and treatment approaches within cardiovascular medicine.

Dr. Hochman’s leadership extends within the National Institutes of Health (NIH) community as well. She has chaired the NIH’s Women’s Health Initiative Advisory Committee and served on multiple Data and Safety Monitoring Boards, underscoring her enduring commitment to the rigor, safety, and ethical oversight of clinical trials that seek to improve health outcomes, especially for women.

Reflecting on her award, Dr. Hochman emphasized the collaborative nature of scientific progress and her dedication to evidence-based patient care. She expressed gratitude for initial and sustained support from the American Heart Association and the NIH, which have been instrumental in funding pivotal randomized clinical trials central to her career achievements. This recognition by the AHA represents not only a personal milestone but also acknowledgement of a transformative era in cardiology research to which she has been integral.

Dr. Hochman’s long-standing affiliation with the AHA is exemplified by her service on numerous advisory and scientific committees, including the Science Advisory Coordinating Committee, Scientific Sessions Planning Committee, and the Women in Cardiology Committee. Her record of accolades from the Heart Association is extensive, featuring the Distinguished Scientist Award, Clinical Research Prize, and mentoring awards that recognize her impact as both investigator and leader.

Her academic pedigree is impressive, with degrees from Harvard Medical School and Harvard University’s Department of Cellular and Developmental Biology, complemented by clinical training at renowned institutions including Brigham and Women’s Hospital and Johns Hopkins University. Dr. Hochman has served on expert panels such as the FDA’s Cardiovascular and Renal Drugs Advisory Committee and the NHLBI Board of External Experts, reflecting her valued expertise in regulatory and advisory capacities.

With over 500 peer-reviewed publications to her name, Dr. Hochman contributes actively to the scientific discourse as an editorial board member of high-impact journals including Circulation, JAMA Cardiology, and the European Heart Journal. Her prolific academic output and editorial roles further consolidate her position as a thought leader dedicated to advancing the field through knowledge dissemination.

Dr. Judith Hochman’s receipt of the 2025 Research Achievement Award at the American Heart Association’s Scientific Sessions underscores the profound and multidisciplinary impact of her work. Through groundbreaking clinical trials, innovative research into sex-specific cardiovascular disease, and influential guideline development, she has indelibly shaped contemporary cardiology, promoting evidence-based improvements in patient outcomes worldwide.

Subject of Research: Cardiovascular clinical research focusing on revascularization strategies and sex differences in ischemic heart disease.

Article Title: Judith S. Hochman, M.D., Honored with 2025 Research Achievement Award by American Heart Association

News Publication Date: October 1, 2025

Web References:
https://newsroom.heart.org/news/nyu-grossman-school-of-medicine-leader-to-receive-the-2025-research-achievement-award?preview=c65f75ed44e29465589c03f6cd669350
https://www.ahajournals.org/doi/full/10.1161/CIR.0b013e318277d6a0?utm
https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001039?utm

Keywords: Cardiovascular disorders, cardiovascular disease, clinical trials, revascularization, ischemic heart disease, gender differences, myocardial infarction, cardiogenic shock, invasive treatment, guideline development, women’s cardiovascular health, clinical research